What's new?

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

Dr. Anderson’s appointment as Partner in the Crossover Fund reflects the venture capital firm’s continuing expansion across the entire value chain of life sciences investments, from seed to later-stage   PARIS, France – October 14, 2020    Sofinnova Partners, a leading European life sciences venture capital firm ba...

Investments in innovative medical devices follow the fund’s initial closing in May 2019   PARIS, France – July 2, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the second investment from its MD Start III Fund, a medtech accelerator...

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Marseille, May 13, 2008.

Marseille, le 13 Mai 2008 – WYPLAY SAS, société pionnière dans le développement de produits Media Center Haute Définition, annonce la finalisation de son 2ème tour de table pour un montant de 10 millions d’euros. Elaia Partners, investisseur leader sur ce second tour de table, et A Plus Finance ont participé à cett...